AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01110044 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix™
Description: Intramuscular, four doses
Study NCT01110044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: Oral, two doses
Study NCT01110044 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix™
Description: Oral, two doses
Study NCT02998437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 500 Mg
Description: Period 1: Amoxicillin 500mg 2 cap., one a day, one day Period 2: Amoxicillin 500mg 2 cap., one a day at 5 day
Study NCT04666454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Adenosine infusion 70 µg/kg/min for 3 hours.
Study NCT04666454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyridamole 200 mg
Description: 200 mg b.i.d
Study NCT04666454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 5 mg Oral Tablet
Description: 5mg b.i.d
Study NCT04666454 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology for takotsubo syndrome
Description: This treatment will vary depending on local routines and the degree of adherence to the recommendations.
Study NCT03158948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nangibotide 0.3 mg/kg
Description: Formulated LR12 peptide
Study NCT03158948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT03158948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nangibotide 1 mg/kg
Description: Formulated LR12 peptide
Study NCT03158948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nangibotide 3 mg/kg
Description: Formulated LR12 peptide
Study NCT03919617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REMD-477
Description: 4-Week, open-label, once weekly subcutaneous injection with 70mg REMD-477.
Study NCT02652234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar, ih, QD，day 1 of cycle 1; Endostar, ih, QD，day 2-15 of cycle 3;
Study NCT02652234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Study NCT04513028 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-Glucan
Description: 500mg (1 capsule) by mouth twice a day for 21 days.
Study NCT02072005 — intervention group
Intervention type: OTHER
Intervention: mSMART smartphone application
Description: This application is an interface that provides subjects with information and questionnaires related to their medication.
Study NCT04511663 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Assertive community treatment
Description: The intervention team consisted of psychiatrists, nurses, clinical psychologists, social workers, rehabilitation teachers. The specific services provided by the team include individual service plan. Each patient got a comprehensive evaluation within one month to establish treatment goals and individual intervention plan, rehabilitation training, family intervention peer support group, individual psychological counseling and crisis intervention.
Study NCT04511663 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Basic public health services.
Description: The control group received regular medical follow-up including symptom and medication evaluation, social function evaluation and physical examination after hospital discharge. The frequency was once a quarter.
Study NCT01898676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex Sodium Extended-release 250mg
Description: Two tablets of Divalproex Sodium Extended-Release 250mg will be given to the subject in two treatment periods
Study NCT01898676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DEPAKOTE 250mg
Description: Two tablets of DEPAKOTE 250mg will be given to the subject in two treatment periods.
Study NCT06629974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental empowerment program
Description: The empowerment program consisted of two parts: the empowerment training program for parents and motivational interviews.~The empowerment training program was prepared to enable parents to carry out the care process more effectively in areas where parents have difficulties caring for their children with autism. Within the scope of the empowerment training program, parents were trained on the importance of play and communication, problems and management in the field of nutrition, sleep problems and management, safety and protection from accidents, and problems and management in the field of self-care.~Ten days after the empowerment training program, two face-to-face motivational interviews were conducted with each participant in the intervention group. Each participant had a one-week break between the first and second motivational interviews. Each motivational interview session lasted approximately 25-30 minutes.
Study NCT02728271 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPC cell infusion
Description: Administration of total lymphatic irradiation, antithymocyte globulins, and high dose cyclophosphamide, followed by the infusion of autologous stem cells.~Patients will not receive any cyclosporin A, rituximab, or azathioprine post transplant.
Study NCT01895140 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Renal denervation device
Study NCT01895140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation device
Study NCT04833192 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: experimental group
Description: DHEAS.24h-UFC,ACTH and cortisol are measured in the experimental group
Study NCT01554592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withdrawal of statin therapy
Description: Participants currently received statin therapy will have their statin stopped for 12 weeks.
Study NCT01554592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin therapy
Description: Participants will continue on stable statin therapy.
Study NCT01841827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Study NCT01841827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03273530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Supported Employment
Description: vocational assessment followed by job placement and on-going work-related social skills revision and reinforcement
Study NCT01255033 — intervention group
Intervention type: DEVICE
Intervention: Monitoring of tissular oxygenation
Description: Equanox: cerebral oxygenation by spectroscopy, near-infrared through forehead and noninvasive devices~Inspectra: tissular oxygenation by spectroscopy, near-infrared through thenar and noninvasive device
Study NCT01934946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation
Description: received 14 days hospitalization for comprehensive rehabilitation
Study NCT01934946 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: home rehabilitation
Description: 6 times home rehabilitation services within 3 months
Study NCT00550121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin C
Study NCT00550121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03423394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Description: The MET intervention will consist of three 45-90 minute telephone delivered sessions that will be staggered to occur 1 week, 1 month, and 2 months after the baseline assessment. The first MET session intervention will involve a counselor using motivational interviewing (MI) strategies to establish an empathic therapeutic relationship and focus learning about the PTSD symptoms the participant is experiencing and exploring ambivalence about seeking treatment services. MET sessions 2 and 3 will focus on identifying and responding to risk factors for dropping out of treatment (increases in ambivalence, avoidance behavior, concerns about stigma, life chaos), identifying and responding to barriers to participant's active engagement in treatment, and facilitating enrollment in alternate therapeutic resources if necessary.
Study NCT03423394 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: TAU will include a written referral list comprised of PTSD resources including information on in-person treatments, self-help, web-based and bibliotherapy options. At the completion of the study, participants in the TAU condition will be offered the MET intervention.
Study NCT01016106 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Swab
Description: During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT laboratories in Lenexa, Kansas.
Study NCT05276713 — intervention group
Intervention type: DRUG
Intervention: Tucidinostat
Description: Tucidinostat in combination with endocrine drugs
Study NCT01328431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Intervention with NRT Initiation
Description: Brief Negotiated Interview is a manual-guided therapy designed for the ED setting. The purpose is to assist subjects to change some aspect of their smoking and to decide to start nicotine replacement therapy while in the ED. It combines techniques from motivational interviewing and stages of change. a 6-week supply of nicotine replacement therapy is given in the form of patches and gum and subjects are encouraged to use both concurrently. Patches come in 21 mg, 14 mg, and 7 mg doses and the dosage is determined based on how many cigarettes per day a subject is smoking. All subjects receive 400 pieces of 2 mg nicotine gum. All subjects complete a referral form for the state's Smokers' Quitline which is then faxed directly to the Quitline's vendor.
Study NCT04072146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg
Description: Cross over bioavailability study
Study NCT04072146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg
Description: Cross over bioavailability study
Study NCT02770040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: INFLIXIMAB (REMICADE) in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution and infused
Study NCT01211665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: In intravenous form (for a daily dose of 1 g/day on treatment days).
Study NCT01211665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral prednisolone used as a taper, with suggested dosages starting at 80 mg and tapering to 5 mg.
Study NCT04211402 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study NCT00575991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid
Description: 3 grams per day of 80% CLA in safflower oil (2.4 grams active CLA isomers in triglyceride form)
Study NCT00575991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Conjugated linoleic acid
Description: 3 grams per day of 80% CLA in safflower oil (2.4 grams active CLA isomers in triglyceride form)
Study NCT00985478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV342
Description: 25 mg once daily - Maximal Tolerated Dose
Study NCT02511704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Multiple dose nicotine
Study NCT00985478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study NCT02390908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate PLUS intervention
Description: The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.
Study NCT02390908 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list PLUS intervention
Description: In addition to treatment as usual, participants will receive handouts with printed information about HIV, the importance of ART adherence, and problematic alcohol use and HIV disease progression. Following their assessment 12 months after their baseline visit, participants will receive the PLUS intervention.
Study NCT02829073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromonics Tinnitus Treatment Program
Description: The Neuromonics Oasis™ treatment device will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
Study NCT02511704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Multiple dose nicotine
Study NCT04282902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pirfenidone
Description: Pirfenidone is administered orally 3 times a day, 2 tablets each time, for a period of 4 weeks or longer
Study NCT01805856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPC piperacillin sodium
Study NCT01805856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEZ, cefazolin sodium
Study NCT03728725 — intervention group
Intervention type: DEVICE
Intervention: Cepheid Gene Xpert MTB/XDR
Description: The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) is an integrated, automated, cartridge-based system for MDR-TB diagnosis that uses the GeneXpert instrument platform. WHO confirmed evidence to support the widespread use of the Xpert MTB/RIF assay in 2010 and the assay has since been widely used in TB programs, but it is only capable of identifying Mycobacterium tuberculosis (Mtb) and detecting RIF resistance. The Xpert MTB/XDR assay will be evaluated for INH and second-line resistance detection, and to recommend its use in diverse clinical settings. The focus of this protocol is the multicentre clinical evaluation.
Study NCT03970811 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate Implants
Description: dental implants are immediately placed after tooth extraction
Study NCT03970811 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Implants
Description: dental implants are immediately placed after tooth extraction
Study NCT03970811 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: temporary restoration
Description: temporary restoration will be placed immediately after implant placement
Study NCT03970811 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: final restoration
Description: final restoration (loading) will be placed 3 months postsurgical
Study NCT03970811 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: final restoration
Description: final restoration (loading) will be placed 3 months postsurgical
Study NCT00567879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Participants received escalating doses of panobinostat until the maximum tolerated dose (MTD) was reached. The starting dose of panobinostat i.v. was 10mg/m\^2 at days 1 and 8 during a 21-day treatment cycle. The oral panobinostat starting dose was 20 mg twice weekly.
Study NCT00567879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Fixed doses of trastuzumab were given in parallel with panobinostat. Trastuzumab i.v. was given weekly according to the instruction in the package insert.
Study NCT01885364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: intravenous injection with normal saline before injection of propofol
Study NCT01885364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: intravenous injection with remifentanil 0.5 mg/kg before injection of propofol
Study NCT01885364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: intravenous injection with remifentanil 0.35 ug/kg before injection of propofol
Study NCT01885364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol
Description: intravenous injection after pretreatment
Study NCT01885364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: intravenous injection after pretreatment
Study NCT01885364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: intravenous injection after pretreatment
Study NCT02435901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alemtuzumab (Campath IH)
Description: Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17
Study NCT02435901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 35/m2 is given daily over 4 days on Day -7 to Day -4.
Study NCT02435901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 70mg/m2 is given daily over 2 days on Day -3 to Day -2.
Study NCT02435901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Immunosuppressant to prevent graft vs host disease is given on Day -1 prior to stem cell infusion
Study NCT02435901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Immunosuppressant to prevent graft vs host disease is given on Day -1.
Study NCT02435901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Immunosuppressant to prevent graft vs host disease is given Day -1 prior to stem cell infusion
Study NCT02435901 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplantation
Description: Human Leukocyte Antigen (HLA) matched or mismatched; related or unrelated hematopoietic stem cells to be transplanted on Day 0.
Study NCT01565161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Health Coaching
Description: The 6-month intervention arm consists of 3 components:~1. In-home coaching visits with a health educator trained in motivational interviewing to encourage behavior change. In addition to 4 monthly in-home coaching visits, participants receive 4 monthly coaching phone calls to supplement the in-person visits.~2. Use of mobile technology to deliver health information by text message - participants receive messages twice weekly for 16 weeks and then weekly for 8 weeks of the program. Those without a phone capable of receiving text messages receive postcards by mail.~3. Printed materials, including educational handouts, newsletters, and activities highlighting target behaviors, sent monthly for 4 months.
Study NCT01565161 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mailed materials
Description: We designed materials for our control group focusing on Developmental milestones during early childhood to provide information that participants would find relevant and helpful for parenting, but that would also not influence intervention behaviors, such as TV viewing or household routines related to sleeping, eating, or television viewing.~Participants received 4 monthly mailing packages, each focusing thematically on one of four milestone domains: motor, language, cognitive and social/emotional. Educational materials were adapted from the Center for Disease Control's Positive Parenting Tips for Healthy Child Development, and the mailing included child-appropriate incentives to reinforce the concepts presented in the educational materials.
Study NCT02943655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined contraceptive pills (microcept)
Description: oral combined contraceptive once daily
Study NCT02943655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medroxyprogesterone acetate (progest)
Description: oral 5 mg medroxyprogesterone acetate daily
Study NCT02943655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mefenamic acid (ponstan forte)
Description: oral 500 mg mefenamic acid three times per day
Study NCT02873884 — intervention group
Intervention type: BEHAVIORAL
Intervention: Case-management
Study NCT03451643 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ENDOSCOPIC PLACEMENT OF EXPANDABLE STENT
Description: PLACEMENT OF AN ENDOSCOPIC SELF EXPANDABLE METAL STENT
Study NCT03451643 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENDOSCOPIC PLACEMENT OF EXPANDABLE STENT
Description: PLACEMENT OF AN ENDOSCOPIC SELF EXPANDABLE METAL STENT
Study NCT02829073 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Device
Description: A placebo device, identical to the Neuromonics Oasis™ device with altered firmware will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
Study NCT01450878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta-epoietin
Description: 100 000UI beta-epoietin injection one hour before organ retrieval
Study NCT03152799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC Remote Ischaemic Pre-Conditioning
Description: intermittent limb ischaemia via a peripheral blood pressure cuff inflation and deflation
Study NCT03152799 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: intermittent peripheral blood pressure cuff inflation and deflation which does not induce a protective cellular response